MindMed works to improve patient outcomes through our pipeline of novel drug candidates and digital therapeutics.
MindMed works to improve patient outcomes through our pipeline of novel drug candidates and digital therapeutics.
MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.
MindMed uses industry-leading drug development expertise in its mission to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.
Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action
Explore MindMed’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.
Our world-class team of drug developers and digital medicine experts was built to advance innovative solutions for the major unmet medical need in brain health disorders.
Robert Barrow
Chief Executive Officer and Board Director
Miri Halperin Wernli, PhD
Executive President
Daniel Karlin, MD, MA
Chief Medical Officer
Schond Greenway, MBA
Chief Financial Officer
Francois Lilienthal, MD, MBA
Chief Commercial Officer
Carrie Liao, CPA
Corporate Controller & Principal Accounting Officer
Robert Silva, PhD
VP, Head of Development
Bridget Walton, MS
VP, Global Regulatory Affairs
Peter Mack, PhD
VP, Pharmaceutical Development
Carole Abel, MBA
VP, Programs and Portfolio Office (PPO)
You are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed